Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 10/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.39 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4341329 | 0.90 | TNK2 (0.46) | ALDH1A1MAPTTSHRNPC1TP53 | |
| SCHEMBL5200051 | 0.87 | TRPC3 (0.42) | ALDH1A1MAPTTSHRNPC1RAB9A | |
| SCHEMBL4339463 | 0.84 | ALDH1A1 (0.41) | ALDH1A1MAPTTSHRTGFBR1KDM4E | |
| SCHEMBL4342554 | 0.83 | ALDH1A1 (0.42) | ALDH1A1MAPTTSHRTGFBR1KDM4E | |
| SCHEMBL4345537 | 0.83 | TGFBR1 (0.49) | ALDH1A1MAPTTSHRNPC1TP53 | |
| SCHEMBL5139647 | 0.81 | TGFBR1 (0.45) | ALDH1A1MAPTTSHRNPC1TP53 | |
| SCHEMBL4343582 | 0.81 | TRPC3 (0.42) | ALDH1A1MAPTTSHRNPC1RAB9A | |
| SCHEMBL4337346 | 0.79 | TRPC3 (0.42) | ALDH1A1MAPTTSHRNPC1RAB9A | |
| SCHEMBL6245229 | 0.78 | TGFBR1 (0.42) | ALDH1A1MAPTTSHRTGFBR1KDM4E | |
| SCHEMBL4342038 | 0.76 | GRIN2B (0.43) | ALDH1A1MAPTTSHRNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612094-B2 | Tri-substituted heteroaryls and methods of making and using the same | BIOGEN IDEC MA INC. (US) | 2009-11-03 | — | — | US | claimed |
| EP-1804801-A2 | METHODS OF TREATING VASCULAR INJURIES | Biogen Idec MA, Inc. (US) | 2007-07-11 | — | — | EP | claimed |
| WO-2006044509-A2 | METHODS OF TREATING VASCULAR INJURIES | BIOGEN IDEC MA INC. (US) | 2006-04-27 | — | — | WO | claimed |
| US-20060063809-A1 | Tri-substituted heteroaryls and methods of making and using the same | BIOGEN MA INC. | 2006-03-23 | — | — | US | claimed |
| CN-1658866-A | Tri-substituted heteroaryls and methods of making and using the same | BIOGEN INC (US) | 2005-08-24 | — | — | CN | claimed |
| EP-1499308-A2 | TRI-SUBSTITUTED HETEROARYLS AND METHODS OF MAKING AND USING THE SAME | BIOGEN, INC. (US) | 2005-01-26 | — | — | EP | claimed |
| WO-2003087304-A2 | TRI-SUBSTITUTED HETEROARYLS AND METHODS OF MAKING AND USING THE SAME | BIOGEN, INC. (US) | 2003-10-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063809-A1 | Tri-substituted heteroaryls and methods of making and using the same | ALK, ACVR1, ACVRL1 | ALDH1A1 113/4885MAPT 4319/4885TSHR 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.